A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia

BXCL501-304

A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.

2022-12-14

2023-09-11

2023-09-11

Terminated

Early phase I

13

Inclusion Criteria: 1. All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria 2. Episodes of psychomotor agitation (e.g., kick, bite, flailing) 3. Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior 4. A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living 5. Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf 6. Subjects who are deemed to be medically appropriate for study participation by the principal investigator 7. Participants who agree to use a medically acceptable and effective birth control method Exclusion Criteria: 1. Subjects with dementia or other memory impairment not due to probable AD. 2. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function. 3. Subjects with agitation caused by acute intoxication. 4. Subjects with significant risk of suicide or homicide per the investigator's assessment. 5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location. 6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia. 7. Subjects with laboratory or ECG abnormalities. 8. Subjects who have received an investigational drug within 30 days prior to Screening. 9. Subjects who are currently suffering from substance abuse. 10. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Double-Blinded', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 13, 'type': 'ACTUAL'}}

2023-12-11